Bio-Techne Corp.
(NASDAQ : TECH)

( )
TECH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.93%158.000.0%$686.24m
AMGNAmgen, Inc. -0.25%250.581.5%$604.45m
GILDGilead Sciences, Inc. -0.47%66.021.0%$437.82m
VRTXVertex Pharmaceuticals, Inc. -1.24%299.231.9%$414.73m
REGNRegeneron Pharmaceuticals, Inc. -1.91%636.342.6%$364.61m
ILMNIllumina, Inc. -3.10%213.023.3%$317.77m
SNSSSunesis Pharmaceuticals, Inc. -0.98%4.060.7%$283.81m
NVAXNovavax, Inc. -8.19%39.3775.7%$258.88m
BIIBBiogen, Inc. -0.94%217.581.8%$192.12m
BNTXBioNTech SE -5.19%152.040.0%$149.19m
GOVXGeoVax Labs, Inc. 0.44%2.260.0%$119.92m
BMRNBioMarin Pharmaceutical, Inc. -0.20%94.844.2%$100.34m
SAVACassava Sciences, Inc. 27.26%25.720.0%$95.08m
CRSPCRISPR Therapeutics AG -5.42%71.740.6%$92.05m
PACBPacific Biosciences of California, Inc. -4.88%7.616.2%$87.70m

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics & Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.